Trevena Inc
NASDAQ:TRVN 10:49:47 AM EDT
| Market Cap (Intraday) | 243.52M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.60 |
| 50-Day MA | $1.83 |
| 200-Day MA | $2.25 |
Trevena Inc Stock, NASDAQ:TRVN
955 Chesterbrook Boulevard, Suite 110, Chesterbrook, Pennsylvania 19087
United States of America
Phone: +1.610.354.8840
Number of Employees: 25
Description
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.